Pharmaceutical companies are reluctant to invest in research and development (R&D) of
products for neglected tropical diseases (NTDs) mainly due to the low ability-to-pay of health …

International responses to the outbreak of SARS, the spread of HIV/AIDS, and the promotion
of health as a human right all demonstrate how global politics have a profound effect on the …

The transition from international to global health reflects the rapid growth in the numbers and
nature of stakeholders in health, as well as the constant change embodied in the process of …

In the last decade, the organization of pharmaceutical research on neglected tropical
diseases has undergone transformative change. In a context of perceived “market failure,” …

Infectious diseases are among the main causes of death and disability in developing
countries, and they are a major reason for the health disparity between rich and poor …

The emergence of global health partnerships (GHPs) towards the end of the twentieth
century reflected concerns about slow progress in access to essential medicines, including …

Background to the Debate This PLoS Medicine Debate examines the different approaches
that can be taken to tackle neglected tropical diseases (NTDs). Some commentators, like …

Collaboration between organizations in different sectors of the economy is not a new
development, but it has become increasingly dominant in the discourse on public sector …

​ Hailed by some as fundamental pillar of global governance, and criticized by others as
manifestation of 'top-down globalism', multi-stakeholder partnerships have become the new …

The article analyses the involvement of pharmaceutical companies from emerging markets
in global health governance. It finds that they play a central role as low-cost suppliers of …